D06BB10 imiquimod

DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals

非健保收載 TFDA 在效許可證 4 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 4 張;以下列出 4 個品項。

無外觀照
樂得美乳膏5%
無外觀照
無發乳膏
無外觀照
“羅得”安疣乳膏
無外觀照
優克寧乳膏 5%

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. Imiquimod乳膏可用於局部治療:成人生殖器外部的疣、肛門周圍的疣和濕性尖疣。免疫功能正常之成人、經切片證實之原發性表淺型基底細胞癌。腫瘤直徑小於2公分、並不得位於手及腳。而且必須是不適合用外科手術切除的腫瘤、病人必須能夠再追蹤。免疫功能正常之成人、臨床上診斷為臉部及頭皮的典型、非過度角化、非肥厚型的日光性角化症(Actinickeratosis)。其患處大小或數量無法以冷凍法治療、或效果有限而且不適合使用其他局部療法者。
  2. 治療成人生殖器外部的疣、肛門周圍的疣和濕性尖疣。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 imiquimod (商品名 Imiquimod) · 仿單更新 2025-01-31

1 INDICATIONS AND USAGE Imiquimod Cream is indicated for the topical treatment of: • Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults. ( 1.1 ) • Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults with a maximum tumor diameter of 2.0 cm on trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. ( 1.2 ) • External genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older. ( 1.3 ) 1.1 Actinic Keratosis Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults. 1.2 Superficial Basal Cell Carcinoma Imiquimod Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. Establish the histological diagnosis of superficial basal cell carcinoma prior to treatment. The safety and effectiveness of Imiquimod Cream have not been established for other types of basal cell carcinomas (BCC), including nodular and morpheaform (fibrosing or sclerosing) types. 1.3 External Genital Warts Imiquimod Cream is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。